Sexually transmitted infections (STIs) constitute a major public health problem in the UK and may result in very costly complications. Many STIs pose the risk of a number of adverse pregnancy outcomes including miscarriage, still birth, preterm delivery, low birth weight and ophthalmia neonatorum. National guidelines for the management of STIs are produced and regularly revised by the British Association of Sexual Heath and HIV. This review outlines the latest recommended treatment options during pregnancy for the commonly encountered STIs.
House of Commons Health Committee. Sexual Health: Third Report of Session 2002–3, Vol. 1. Health Committee Publications, London, UK (2003).
5.
FlemingDTWasserheitJN. From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to the sexual transmission of HIV infection. Sex. Trans. Infect. 75, 3–17 (1999).
6.
AndrewsWWGoldenbergRLMercerB. The preterm prediction study: association of second trimester genitourinary chlamydia infection with subsequent spontaneous preterm birth. Am. J. Obstet. Gynecol. 1(83), 662–668 (2000).
7.
BrocklehurstPRooneyG. Interventions for treating genital Chlamydia trachomatis infection in pregnancy. Cochrane Database Syst. Rev. 2, CD000054 (2000).
8.
HookEWHandsfieldHH. Gonococcal infections in the adult. In: Sexually Transmitted Diseases (4th Edition). HolmesKKSparlingFPStammWE (Eds). McGraw-Hill Companies, NY, USA, 627 (2008).
9.
AlgerLSLovchikJCHebelJRBlackmonLRCrenshawMC. The association of Chlamydia trachomatis, Neisseria gonorrhoeae, and group B streptococci with preterm rupture of membranes and pregnancy outcome. Am. J. Obstet. Gynecol. 159(2), 397–404 (1988).
10.
MartinDHCammarataCVan der PolB. Multicentre evaluation of AMPLICOR and automated COBAS AMPLICOR CT/NG tests forNeisseria gonorrhoeae. J. Clin. Microbiol. 38, 3544–3549 (2000).
11.
Van der Pol B, Ferrero DV, Buck-Barrington L et al. Multicentre evaluation of the BDProbe Tec ET system for detection of Chlamydia trachomatis and Neisseria gonorrhoeae in urine specimens, female endocervical and male urethral swabs. J. Clin. Microbiol. 39, 1008–1016 (2001).
12.
SchachterJCherneskyMAWillisDE. Vaginal swabs are the specimens of choice when screening for Chlamydia trachomatis and Neisseria gonorrhoeae: results from a multicentre evaluation of the APTIMA assays for both infections. Sex. Trans. Dis. 32, 725–728 (2005).
13.
Demonstrates that self-taken vaginal swabs are of equivalent sensitivity to endocervical swabs.
14.
ChisholmSMoutonJLewisDNicholsTIsonCALivermoreDM. Cephalosporin MIC creep among gonococci: time for a pharmacodynamics rethink?J. Antimicrob. Chemother. 65, 2141–2118 (2010).
15.
Data highlighting the issue of decreased susceptibility of gonococci to third-generation cephalosporins.
16.
FuruyaRNakayamaHKanayamaAIn vitro synergistic effects of double combinations of β lactams and azithromycin against clinical isolates ofNeisseria gonorrhoeae. J. Infect. Chemother. 12, 172–176 (2006).
17.
SathiaLEllisBPhilipSWinstonASmithA. Pharyngeal gonorrhoea — is dual therapy the way forward?Int. J. STD AIDS18, 647–648 (2007).
18.
AlexanderJMSheffieldJSSanchezPJMayfieldJWendelGDJr.Efficacy of treatment for syphilis in pregnancy. Obstet. Gynaecol. 93, 5–8 (1999).
19.
SheffieldJMSanchezPJMorrisG. Congenital syphilis after maternal treatment for syphilis during pregnancy. Am. J. Obstet. Gynecol. 186, 569–573 (2002).
20.
McFarlinBLBottomsSFDockBSIsadaNB. Epidemic syphilis: maternal factors associated with congenital infection. Am. J. Obstet. Gynecol170, 535–540 (1994).
21.
MascolaLPelosiRAlexanderCE. Inadequate treatment of syphilis in pregnancy. Am. J. Obstet. Gynecol. 150, 945–947 (1984).
22.
ChisholmCKatzVMcDonaldTBowesWAJr.Penicillin desensitisation in the treatment of syphilis during pregnancy. Am. J. Perinatol. 14, 553–554 (1997).
23.
KeetIPMLeeFKvan GriensvenGJLangeJMNahmiasACoutinhoRA. Herpes simplex virus type 2 and other genital ulcerative infections as a risk factor for HIV-1 acquisition. Genitourin. Med. 66, 330–333 (1990).
24.
WaldAHuangMLCarrellDSelkeSCoreyL. Polymerase chain reaction for detection of herpes simplex virus (HSV) DNA on mucosal surfaces: comparison with HSV isolation in cell culture. J. Infect. Dis. 188, 1345–1351 (2003).
25.
BrownZAWaldAMorrowAshley RSelkeSZehJCoreyL. Effect of serological status and caesarean delivery on transmission rates of herpes simplex virus from mother to infant. JAMA289, 203–209 (2003).
26.
Reiff-EldridgeRHeffnerCREphrossSATennisPSWhiteADAndrewsEB. Monitoring pregnancy outcomes after prenatal drug exposure through prospective pregnancy registries: a pharmaceutical company commitment. Am. J. Gynecol. 182, 159–163 (2000).
27.
Safety data supporting use of acyclovir during pregnancy.
28.
BrownZASelkeSZehJ. The acquisition of herpes simplex virus during pregnancy. N. Engl. J. Med. 337, 509–515 (1997).
29.
ScottLSanchezPJJacksonPLZerayFWendelGDJr.Acyclovir suppression to prevent caesarean delivery after first-episode genital herpes. Obstet. Gynecol. 87, 69–73 (1996).
30.
ProberCGSullenderWMYasukawaLLAuDSYeagerASArvinAM. Low risk of herpes simplex virus infections in neonates exposed to the virus at the time of vaginal delivery to mothers with recurrent genital herpes. N. Engl J. Med. 316, 240–244 (1987).
31.
BrownZABenedettiJAshleyR. Neonatal herpes simplex virus infection in relation to asymptomatic viral shedding at the time of labour. N. Engl. J. Med. 324, 1247–1252 (1991).
32.
SheffieldJSHollierLMHillJBStuartGSWendelGD. Acyclovir prophylaxis to prevent herpes simplex virus recurrence at delivery: a systematic review. Obstet. Gynaecol. 102, 1396–1403 (2003).
AultK. Human papilloma virus infections: diagnosis treatment and hope for a vaccine. Obstet. Gynecol. Clin. North Am. 30, 809–817 (2003).
35.
BrothertonJMFridmanMMayCLChappellGSavilleAMGertigDM. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet377, 2085–2092 (2011).
36.
First report of an early decrease in high-grade cervical abnormalities within 3 years of the implementation of a national vaccination program.
37.
DonovanBFranklinNGuyR. Quadrivalent human papilloma virus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infect. Dis. 11, 39–44 (2011).
38.
Quadrivalent human papilloma virus vaccine has resulted in decreased burden of genital warts.
39.
SmithEMRitchieJMYankowitzJ. Human papilloma virus prevalence and types in newborns and parents. Sex. Trans. Dis. 31, 57–62 (2004).
40.
BeutnerKRWileyD. Recurrent external genital warts: a literature review. Papilloma Virus Rep. 8, 69–74 (1997).
41.
KlebanoffMACareyJCHauthJC. Failure of metronidazole to prevent preterm delivery among pregnant women with asymptomatic Trichomonas vaginalis infection. N. Engl. J. Med. 345, 487–493 (2001).
42.
CotchMFPastorekJG2ndNugentRP. Trichomonas vaginalis associated with low birth weight and preterm delivery. Sex. Trans. Dis. 24, 353–360 (1997).
43.
TrintisJEpieNBossRReidelS. Neonatal Trichomonas vaginalis infection: a case report and review of literature. Int. J. STD AIDS21, 606–607 (2010).
44.
BickleyLSKrisherKKPunsalangATrupeiMAReichmanRCMenegusMA. Comparison of direct fluorescent antibody, acridine orange, wet mount and culture for detection of Trichomonas vaginalis in women attending a public sexually transmitted diseases clinic. Sex. Trans. Dis. 16(3), 127–131 (1989).
45.
CziezelAERockenbauerM. A population based case—control teratologic study of oral metronidazole treatment during pregnancy. Br. J. Obstet. Gynaecol. 105, 322–327 (1998).
46.
HayPELamontRFTaylor-RobinsonDMorganDJIsonCAPearsonJ. Abnormal bacterial colonisation of the genital tract and subsequent preterm delivery and late miscarriage. Br. J. Med. 308, 295–298 (1994).
47.
NelsonDBMaconesG. Bacterial vaginosis in pregnancy: current findings and future directions. Epidemiol. Rev. 24, 102–108 (2002).
AmselRTottenPASpiegelCAChenKCEschenbachDHolmesKK. Non-specific vaginitis. Diagnostic criteria and microbial and epidemiological associations. Am. J. Med. 74, 14–22 (1983).
50.
NugentRPKrohnMAHillierSL. Reliability of diagnosing bacterial vaginosis is improved by a standardised method of Gram stain interpretation. J. Clin. Microbiol. 29, 297–301 (1991).
51.
IsonCAHayPE. Validation of a simplified grading of gram stained vaginal smears for use in genitourinary medicine clinics. Sex. Trans. Infect. 78, 413–415 (2002).
52.
NygrenPFuRFreemanMBougatsosCKlebanoffMGuiseJM. Preventative services task force. Evidence on the benefits and harms of screening and treatment patients who are asymptomatic for bacterial vaginosis: an update review for the US Preventative Services Task Force. Ann. Intern. Med. 148, 220–233 (2008).
53.
Meta-analysis that did not find any benefit in screening and treating low-risk women with asymptomatic bacterial vaginosis.
54.
HauthJCGoldenbergRLAndrewsWWDuBardMBCopperRL. Reduced incidence of preterm delivery with metronidazole and erythromycin in women with bacterial vaginosis. N. Engl. J. Med. 333, 1732–1736 (1995).
55.
McDonaldHMO'LoughlinJAVigneswaranR. Impact of metronidazole therapy on preterm birth in women with bacterial vaginosis flora (Gardnerella vaginalis): a randomised placebo-controlled trial. Br. J. Obstet. Gynaecol. 104, 1391–1397 (1997).
56.
MoralesWJSchorrSAlbrittonJ. Effect of metronidazole in patients with preterm birth in preceding pregnancy and bacterial vaginosis: a placebo-controlled, double-blind study. Am. J. Obstet. Gynecol. 171, 345–349 (1994).
57.
KoumansEHMarkowitzLEHoganV. For the CDC BV Working Group. Indications for therapy and treatment recommendations for bacterial vaginosis in non-pregnant and pregnant women: a synthesis of data. Clin. Infect. Dis. 35, S152–S172 (2002).
58.
ColliELandoniMParazinniF. Treatment of male partners and recurrence of bacterial vaginosis: a randomised trial. Genitourin. Med. 73, 267–270 (1997).
